Are anti-ganglioside antibodies detectable in serum from patients with critical illness myopathy and polyneuropathy?


  • A. Martínez-Piñeiro Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, (Barcelona), Spain
  • A. Ramos Fransi Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, (Barcelona), Spain
  • M. Almendrote Muñoz Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, (Barcelona), Spain
  • G. Lucente Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, (Barcelona), Spain
  • E. Martinez Caceres Inmunology Laboratory for Researching and Diagnosis Aplications (LIRAD) Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona (Barcelona), Spain
  • I Ojanguren Saban Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain
  • H. Perez Molto Critical Care Unit, Department of Intensive Care Medicine, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain Universitat Autonoma of Barcelona
  • Vitoria Rubio S Critical Care Unit, Department of Intensive Care Medicine, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain Universitat Autonoma of Barcelona
  • J. Coll-Canti Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, (Barcelona), Spain


Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are the most common cause of acquired weakness in intensive care units (ICU). However, its exact pathogenesis remains unclear. Abnormal excitability of muscle due to a sodium channelopathy is one of the mechanisms proposed. The aim of this study is to test for the presence of anti-ganglioside antibodies in serum from patients with CIM or both combined CIM/CIP, since there is evidence that they can cause reversible dysfunction of voltage-gated sodium channels.

Methods: In a prospective way, we studied 35 patients admitted in ICU by weekly EMG. When positive spontaneous activity (PSA) was detected, a muscle biopsy was performed. Twenty patients met criteria of CIM; five of them also developed overlapping CIP. We did not detect any kind of abnormality in 10 patients during the follow up period. Sera were analyzed for the presence of anti-ganglioside antibodies (Ganglioside-profile 2 Euroline, Euroimmun).

Results: Overall, positive reactivity against anti-GT1b was found in one patient with CIM, representing 2.8% (1/35) of the total sample.

Conclusion: Reduced percentage of patients affected of CIM or CIM/CIP exhibits positive reactive against anti-ganglioside antibodies. Thus, it could be suggested they do not play a primary role in their pathogenesis.


Key words: Critical illness myopathy, critical illness polineuropathy, difficult weaning, channelopathy, muscle fiber inexcitability, anti-ganglioside antibodies





(1) Mac Farlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet 1977; 2:615

(2) Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984; 47:1223-1231

(3) Lacomis D, Giulani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996; 40:645-654

(4) Lacomis D. Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve 2000; 23:1785-1788

(5) Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Provonost PJ, Needham DM. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Medicine 2007; 33:1876-1891

(6) Bercker S, Weber-Carstens S, Deja M, Grimm C, Wolf S, Behse F, Busch T, Falke KJ, Kaisers U. Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33:711-715

(7) Hough CL, Steinberg KP, Taylor Thompson B, Rubenfeld GD, Hudson LD. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009; 35:63-68

(8) Tennilä A, Salmi T, Pettilä V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 2000; 26:1360-63

(9) de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, van der Meché FG. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29:2281-2286

(10) De Jonghe B, Sharsar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, Cerf C, Renaud E, Mesrati F, Carlet J, Raphaël JC, Outin H, Bastuji-Garin S; Groupe de Réflexion et d’Etude des Neuromyopathies en Réanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859-2867

(11) Bednarik J, Vondracek P, Dusek L, Moravcova E, Cundrle I. Risk factors for critical illness polyneuromyopathy. J Neurol 2005; 252: 343-351

(12) Witt NJ, Zochodone DW. Bolton CF, Grand’Maison F, Wells G, Young GB, Sibbald WJ. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99:176-184

(13) Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64: 1348-1353

(14) Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar A, Garnacho-Montero MC, Moyano-Del-Estad MR. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001; 27:1288-1296

(15) Latronico N, Shehu I, Seghelini E. Neuromuscular sequelae of critical illness. Curr Opin Crit Care 2005; 11:381-390

(16) Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS; Canadian Critical Care Trials Group. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348:683-693.

(17) Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry 2008; 79:838-841

(18) Novak KR, Nardelli P, Cope TC, Filatov G, Glass JD, Khan J, Rich MM. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest 2009; 119:1150-1158

(19) Z’Graggen WJ, Lin CS, Howard RS, Beale RJ, Bostock H. Nerve excitability changes in critical illness polyneuropathy. Brain 2006; 129:2461-2470

(20) Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998; 43:171-179

(21) Allen DC, Ramamurthy A, Mills KR. Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy

(22) Z’Graggen WJ, Brander L, Tuchscherer D, Scheidegger O, Takala J, Bostock H. Muscle membrane dysfunction in critical illness myopathy assessed by velocity recovery cycles. Clin Neurophysiol. 2011; 122:834-41

(23) Rich MM, Pinter MJ. Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol 2003; 547: 555-566

(24) Filatov GN, Rich MM. Hyperpolarized shifts in the voltage dependence of fast inactivation of Nav1.4 and Nav1.5 in a rat model of critical illness myopathy. J Physiol 2004; 559:813-820

(25) Teener JW, Rich M. Dysregulation of sodium channel gating in critical illness myopathy. J Muscle Res Cell Motil 2006; 27:291-296

(26) Kraner SD, Novak KR, Wang Q, Peng J, Rich M. Altered sodium channgel-protein associations in critical illness myopathy. Skelet Muscle. 2012; 2:17

(27) Button B, Baker RD, Vertrees RA, Allen SE, Brodwick MS, Kramer GC. Quantitative assessment of a circulating depolarizing factor in shock. Shock 2001; 15:239-244

(28) Haeseler G, Foadi N, Wiegand E, Ahrens J, Krampfl K, Dengler R, Leuwer M. Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channgels at depolarized membrane potentials. Crit Care Med 2008; 36:1239-1247

(29) Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988b; 23:440-447

(30) Sheikh KA et al. The distribution of ganglioside-like moieties in peripheral nerve. Brain 1999; 122:449-460

(31) Hafer-Macko C, Hsieh S-T, Li CY, Ho TW, Sheikh K, Cornblath DR, McKhan GM, Asbury AK, Griffin JW. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40: 635-44

(32) Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 1995; 37: 436-42

(33) Weber F, Reinhardt R, Aulkemeyer P, Brinkmeier H. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels. Muscle Nerve 2000; 23:1414-1420

(34) Kuwabara S, Ogawara K, Sung JY, Mori M, Kanai K, Hattori T, Yuki N, Lin CS, Burke D, Bostock H. Differences in membrane properties of axonal and demyelinating Guillain-Barré Syndromes. Ann Neurol 2002; 52:180-187

(35) Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Scie U S A 2004; 101:11404-11409

(36) Horstman AL, Bauman SJ, Kuehn MJ. Lipopolysaccharide 3-deoxy-D.manno-octusolonic acid (Kdo) core determines bacterial association of secreted toxins. J Biol Chem 2004; 279:8070-8075

(37) Usuki S, Nakatani Y, Taguchi K, Fujita T, Tanabe S, Ustunomiya I, Gu Y, Cawthraw SA, Newell DG, Pajaniappan M, Thompson SA, Ariga T, Yu RK. Topology and patch-clamp analysis of the sodium channel in relationship to the anti-lipid a antibody in campylobacteriosis. J Neurosci Res 2008; 86:3359-3374

(38) Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710

(39) Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-29

(40) Helliwell TR, Wilkinson A, Griffiths RD, Mc Clelland P, Palmer TE, Bone JM. Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol 1998; 24:507-517

(41) Ohsawa T, Miyatake T, Yuki N. Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons. Neurosci Lett 1993; 157:167-170

(42) Willison HJ,O’Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, Fuhr P, Ford H, Hahn A, Renaud S, Katifi HA, Ponsford S, Reuber M, Steck A, Sutton I, Schady W, Thomas PK, Thompson AJ, Vallat JM, Winer J. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124:1968-1977

(43) Rojas-Garcia R, Gallardo E, De Luna N, Juarez C, Martinez-Hernandez E, Carvajal A, Casasnovas C, Fages E, Davila-González P, Illa . Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(alpha2-3)Gal. J Neurol Neurosurg Psychiatry 2010; 81:623-628

(44) Perez Ca, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J. 2002; 8:384-394

(45) Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, IllaI, Zielased J, Hughes RA. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999; 6:71-77

(46) Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care 2008;


(47) Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hébert PC. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007; 146:193-203

(48) Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effecs of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997; 23:1144-1149




Cómo citar

Martínez-Piñeiro A, Ramos Fransi A, Almendrote Muñoz M, Lucente G, Martinez Caceres E, Ojanguren Saban I, Perez Molto H, Rubio S V, Coll-Canti J. Are anti-ganglioside antibodies detectable in serum from patients with critical illness myopathy and polyneuropathy?. Rev Med Trujillo [Internet]. 4 de febrero de 2020 [citado 23 de junio de 2024];15(1). Disponible en: